Discussion about this post

User's avatar
The IVD Manager Evolution's avatar

A very relevant point: downturns do not create brand strength, they reveal whether it was truly there in the first place.

From an in-vitro diagnostics perspective, I would add that recessions make customers not only more price-sensitive, but even more risk-sensitive.

When budgets tighten, laboratories and healthcare organisations become more cautious about changing suppliers, introducing new platforms or accepting operational disruption. In this environment, brand strength is built less through awareness alone and more through accumulated evidence: reliable service, uptime, continuity of supply, successful LIS integration, validated performance and the ability to consistently deliver what was promised.

This is also why cutting marketing indiscriminately can be dangerous. The answer is not necessarily to spend more, but to become more selective: focus on strategic accounts, installed-base development, customer retention, evidence-based communication and stronger sales enablement.

I would add one important qualification to the article: trust alone is not enough. In IVD, trust must ultimately be translated into measurable economic value. A strong supplier must be able to demonstrate lower total cost of ownership, fewer reruns, reduced downtime, better use of technical staff and greater workflow predictability.

The installed base also becomes a critical defensive asset during difficult market conditions. Satisfied customers are less likely to switch and create opportunities for cross-selling, new assays, platform upgrades, multi-site expansion and reference-site development.

That is what makes a diagnostic brand resilient.

In difficult markets, the strongest brands are not simply the most visible or the cheapest. They are the ones that reduce uncertainty for the customer while continuing to prove their value.

No posts

Ready for more?